Literature DB >> 15764042

Oral lichenoid eruption secondary to imatinib (Glivec).

P Ena1, F Chiarolini, G M Siddi, A Cossu.   

Abstract

BACKGROUND: Oral lichenoid drug eruption (OLE) is a self-restricted inflammatory condition usually secondary to a variety of drugs and dental materials (mercury, gold), and rarely to immunomodulators and new antineoplastic agents such as imatinib mesylate (Glivec). OLE clinical features are reminiscent of lichen planus and include symmetric and asymptomatic, erythematous, reticulated and painful ulcerated plaques. Histological examination reveals perivascular lymphocytic infiltrate and the presence of eosinophils that obscures the dermal-epidermal junction, with acanthosis and mild hyperkeratosis.
METHODS: A 62-year-old man was treated with Glivec for metastatic gastrointestinal stromal tumour (GIST).
RESULTS: The patient presented with grey-violaceous plaques on both cheek mucosal surfaces and the lateral sides of the tongue and labial mucosa, with a reticular pattern resembling oral lichen planus. These lesions appeared approximately 1 year after therapy and partially subsided in about 10 weeks, to clear after topical corticosteroids and oral omeprazole. The diagnosis of OLE induced by imatinib was confirmed by histological biopsy evaluation; immunohistochemical analysis revealed intense immunoreactivity with only cytokeratins 5/6 and 14 in the epithelium of affected mucosa. All laboratory investigations proved asiderotic anaemia but excluded infectious causes.
CONCLUSION: It is believed that this patient developed imatinib-induced OLE; this relationship with therapy rather than the underlying disease rules out a paraneoplastic reaction, and negative immunofluorescence excluded autoimmune dermatosis. In addition, we propose that these lesions are correlated with abnormal expression of some cytokeratins directly caused by this drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15764042     DOI: 10.1080/09546630410015556

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  6 in total

Review 1.  Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.

Authors:  Emmanuelle Vigarios; Joel B Epstein; Vincent Sibaud
Journal:  Support Care Cancer       Date:  2017-02-22       Impact factor: 3.603

2.  Imatinib-induced Stevens-Johnsons syndrome.

Authors:  Praveen Jha; D Himanshu; Nirdesh Jain; Ajay Kumar Singh
Journal:  BMJ Case Rep       Date:  2013-01-23

3.  Lichenoid drug eruption due to imatinib mesylate.

Authors:  Anuradha Bhatia; Bimal Kanish; Paulina Chaudhary
Journal:  Int J Appl Basic Med Res       Date:  2015 Jan-Apr

4.  Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report.

Authors:  Arthur Schmouchkovitch; Héloïse Herry; Philippe Thuillier; Véronique Kerlan; Camille Fleuret; Guy Le Toux; Sylvie Boisramé
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

5.  Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib.

Authors:  Gian Paolo Bombeccari; Umberto Garagiola; Francesco Pallotti; Margherita Rossi; Massimo Porrini; Aldo Bruno Giannì; Francesco Spadari
Journal:  Maxillofac Plast Reconstr Surg       Date:  2017-12-05

6.  Generalized lichenoid drug eruption associated with imatinib mesylate therapy.

Authors:  Sudip Kumar Ghosh
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.